medmix (MEDX) Stock Overview
Designs, produces, and sells high-precision devices and services in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MEDX Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
medmix AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.61 |
| 52 Week High | CHF 13.02 |
| 52 Week Low | CHF 8.10 |
| Beta | 0.80 |
| 1 Month Change | 0.94% |
| 3 Month Change | -3.04% |
| 1 Year Change | -18.16% |
| 3 Year Change | -63.21% |
| 5 Year Change | n/a |
| Change since IPO | -80.43% |
Recent News & Updates
Narrative Update • Jun 02
MEDX: Steady Assumptions And Dividend Initiation Will Support Future Upside Potential
Analysts have kept their CHF 15.97 price target on medmix broadly in line with prior estimates, pointing to only marginal tweaks to key model inputs such as the discount rate, long term revenue growth, profit margin assumptions and the future P/E they apply to the stock. What's in the News No recent company specific news items for medmix are available from the provided sources.Narrative Update • May 17
MEDX: Dividend Initiation And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their CHF 15.97 price target on medmix unchanged, citing only modest tweaks to their discount rate and future P/E assumptions rather than any major shift in the company story. What's in the News medmix AG announced an annual dividend of CHF 0.10 per share.Narrative Update • Apr 29
MEDX: Stable Dividend And Consistent Assumptions Will Support Future Upside Potential
Analysts now place the medmix price target at CHF 15.97, with the updated view largely grounded in refreshed assumptions for the discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior expectations. What's in the News medmix AG set an annual dividend of CHF 0.10 per share, with payment scheduled for April 22, 2026 (Key Developments).Narrative Update • Apr 12
MEDX: Stable Dividend Reset And Higher Required Return Will Support Upside
Analysts now keep their fair value estimate for medmix steady at CHF 15.97, citing only minor technical adjustments to inputs such as the discount rate, long term revenue growth, profit margin, and future P/E assumptions rather than any material change in the outlook. What's in the News medmix AG announced an annual dividend of CHF 0.1000 per share, payable on April 22, 2026, with an ex dividend date of April 20, 2026 and a record date of April 21, 2026 (Key Developments).Recent updates
Narrative Update • Jun 02
MEDX: Steady Assumptions And Dividend Initiation Will Support Future Upside Potential
Analysts have kept their CHF 15.97 price target on medmix broadly in line with prior estimates, pointing to only marginal tweaks to key model inputs such as the discount rate, long term revenue growth, profit margin assumptions and the future P/E they apply to the stock. What's in the News No recent company specific news items for medmix are available from the provided sources.Narrative Update • May 17
MEDX: Dividend Initiation And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their CHF 15.97 price target on medmix unchanged, citing only modest tweaks to their discount rate and future P/E assumptions rather than any major shift in the company story. What's in the News medmix AG announced an annual dividend of CHF 0.10 per share.Narrative Update • Apr 29
MEDX: Stable Dividend And Consistent Assumptions Will Support Future Upside Potential
Analysts now place the medmix price target at CHF 15.97, with the updated view largely grounded in refreshed assumptions for the discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior expectations. What's in the News medmix AG set an annual dividend of CHF 0.10 per share, with payment scheduled for April 22, 2026 (Key Developments).Narrative Update • Apr 12
MEDX: Stable Dividend Reset And Higher Required Return Will Support Upside
Analysts now keep their fair value estimate for medmix steady at CHF 15.97, citing only minor technical adjustments to inputs such as the discount rate, long term revenue growth, profit margin, and future P/E assumptions rather than any material change in the outlook. What's in the News medmix AG announced an annual dividend of CHF 0.1000 per share, payable on April 22, 2026, with an ex dividend date of April 20, 2026 and a record date of April 21, 2026 (Key Developments).Narrative Update • Mar 29
MEDX: Stable Dividend Outlook And Higher Required Return Will Support Upside
Analysts now maintain their price target for medmix at CHF 15.97, with minor adjustments to the discount rate, long-term revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News medmix AG announced an annual dividend of CHF 0.10 per share, payable on April 22, 2026, with an ex date of April 20, 2026, and record date of April 21, 2026 (Key Developments).Narrative Update • Mar 13
MEDX: Higher Required Return Will Still Support Future Upside Potential
Analysts have trimmed their price target on medmix by roughly CHF0.87 to reflect a mix of slightly higher revenue growth assumptions, a higher discount rate, lower expected profit margins and a higher projected P/E multiple. Valuation Changes Fair Value: revised from CHF16.83 to CHF15.97, a reduction of about 5% in the implied equity value per share.Narrative Update • Feb 27
MEDX: Slightly Higher Return Hurdle Will Still Support Future Upside Potential
Analysts have reduced their price target on medmix from CHF 17.50 to about CHF 16.83, reflecting slightly more conservative assumptions on revenue growth, profit margins, the discount rate, and the future P/E ratio. Valuation Changes Fair Value: Adjusted from CHF 17.50 to about CHF 16.83, a reduction of roughly 3.8%.Narrative Update • Feb 12
MEDX: Stable Long Term Assumptions Will Support Future Upside Potential
Analysts are keeping their price target for medmix steady at CHF 17.50, as recent model updates to the discount rate, revenue growth, profit margin and future P/E assumptions are all relatively small and do not materially change their valuation view. Valuation Changes Fair Value: Model fair value remains unchanged at CHF 17.50.Narrative Update • Jan 28
MEDX: Stable Assumptions And Margins Will Support Future Upside Potential
Analysts have kept their fair value estimate for medmix steady at CHF 17.50. The unchanged target reflects largely consistent assumptions on revenue growth, profit margin and future P/E, along with a small adjustment to the discount rate.Narrative Update • Jan 13
MEDX: Higher Profitability Assumptions Will Support Future Upside Potential
Analysts have lowered their price target on medmix from €19.00 to €17.50, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E expectations. Valuation Changes Fair Value Estimate: reduced from €19.00 to €17.50, a moderate cut to the implied upside for the shares.Analysis Article • Nov 26
medmix AG (VTX:MEDX) Looks Inexpensive But Perhaps Not Attractive Enough
medmix AG's ( VTX:MEDX ) price-to-sales (or "P/S") ratio of 0.8x may look like a very appealing investment opportunity...New Narrative • Sep 04
Advanced Dental And Surgical Launches Will Expand Global Markets
Key Takeaways New advanced and sustainable product launches, along with proprietary platforms, are driving higher-margin growth and diversification across expanding healthcare markets. Strengthened manufacturing and efficiency programs increase margin resilience, operational leverage, and position medmix to capture demand in developed and emerging regions.Analysis Article • Aug 07
Calculating The Fair Value Of medmix AG (VTX:MEDX)
SWX:MEDX 1 Year Share Price vs Fair Value Explore medmix's Fair Values from the Community and select yours Key Insights...Analysis Article • Jun 22
There's No Escaping medmix AG's (VTX:MEDX) Muted Revenues Despite A 28% Share Price Rise
medmix AG ( VTX:MEDX ) shareholders would be excited to see that the share price has had a great month, posting a 28...Analysis Article • Apr 04
medmix AG's (VTX:MEDX) Business And Shares Still Trailing The Industry
When you see that almost half of the companies in the Medical Equipment industry in Switzerland have price-to-sales...Analysis Article • Feb 28
medmix's (VTX:MEDX) Returns On Capital Not Reflecting Well On The Business
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysis Article • Aug 11
medmix AG (VTX:MEDX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
medmix AG ( VTX:MEDX ) shareholders that were waiting for something to happen have been dealt a blow with a 28% share...Analysis Article • Dec 19
medmix (VTX:MEDX) Is Reinvesting At Lower Rates Of Return
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Oct 27
An Intrinsic Calculation For medmix AG (VTX:MEDX) Suggests It's 21% Undervalued
Key Insights medmix's estimated fair value is CHF24.87 based on 2 Stage Free Cash Flow to Equity medmix is estimated to...Analysis Article • Aug 16
Investors Could Be Concerned With medmix's (VTX:MEDX) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analysis Article • Feb 28
There May Be Reason For Hope In medmix's (VTX:MEDX) Disappointing Earnings
The most recent earnings report from medmix AG ( VTX:MEDX ) was disappointing for shareholders. While the headline...Analysis Article • Jan 14
medmix (VTX:MEDX) May Have Issues Allocating Its Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Shareholder Returns
| MEDX | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | -0.6% | -1.2% | 2.2% |
| 1Y | -18.2% | -18.4% | 10.7% |
Return vs Industry: MEDX matched the Swiss Medical Equipment industry which returned -19% over the past year.
Return vs Market: MEDX underperformed the Swiss Market which returned 10.4% over the past year.
Price Volatility
| MEDX volatility | |
|---|---|
| MEDX Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: MEDX has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MEDX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1922 | 2,574 | Rene Willi | www.medmix.swiss |
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs.
medmix AG Fundamentals Summary
| MEDX fundamental statistics | |
|---|---|
| Market cap | CHF 350.19m |
| Earnings (TTM) | CHF 6.40m |
| Revenue (TTM) | CHF 448.00m |
54.7x
P/E Ratio0.8x
P/S RatioIs MEDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDX income statement (TTM) | |
|---|---|
| Revenue | CHF 448.00m |
| Cost of Revenue | CHF 286.10m |
| Gross Profit | CHF 161.90m |
| Other Expenses | CHF 155.50m |
| Earnings | CHF 6.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 36.14% |
| Net Profit Margin | 1.43% |
| Debt/Equity Ratio | 60.6% |
How did MEDX perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/14 07:55 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
medmix AG is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reto Huber | Research Partners AG |
| Eugen Perger | Research Partners AG |
| Edward Hall | Stifel, Equities Research |